New immune cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT04555551
Summary
This is an early-stage study testing the safety of a new treatment called MCARH109, a type of CAR T-cell therapy, for people with advanced multiple myeloma. The treatment involves modifying a patient's own immune cells to target and potentially stop the growth of cancer cells. The main goal is to find the safest dose and understand the side effects in a small group of patients who have already tried at least three other standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Basking Ridge (Limited protocol activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited protocol activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited protocol activities)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited protocol activities)
Harrison, New York, 10604, United States
Conditions
Explore the condition pages connected to this study.